MDX-447

MDX-447 is an investigational **EGFR × CD64 bispecific antibody fragment** developed through a Medarex and Merck KGaA collaboration for EGFR-expressing malignancies. It was constructed by chemically cross-linking humanized Fab fragments directed against epidermal growth factor receptor and the high-affinity immunoglobulin gamma Fc receptor I, thereby bridging EGFR-positive tumor cells to CD64-positive myeloid effector cells and promoting antibody-dependent cellular cytotoxicity and tumor-cell lysis. In a Phase 1 study in advanced solid tumors, weekly intravenous MDX-447 monotherapy had a maximum tolerated dose of 30 mg/m² but produced no objective responses; concomitant G-CSF increased toxicity and prevented meaningful dose escalation. ([link.springer.com](https://link.springer.com/content/pdf/10.1007/s002620050435.pdf))

Other names

BsAb MDX447bispecific antibody MDX447MDX447MDX-447MDX 447